[go: up one dir, main page]

WO2004029089A3 - Nouvelle cible de l’ angiogenese et utilisations - Google Patents

Nouvelle cible de l’ angiogenese et utilisations Download PDF

Info

Publication number
WO2004029089A3
WO2004029089A3 PCT/FR2003/002810 FR0302810W WO2004029089A3 WO 2004029089 A3 WO2004029089 A3 WO 2004029089A3 FR 0302810 W FR0302810 W FR 0302810W WO 2004029089 A3 WO2004029089 A3 WO 2004029089A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnostic
angiogenesis
therapeutic
field
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002810
Other languages
English (en)
Other versions
WO2004029089A2 (fr
Inventor
Fabien Schweighoffer
Silvere Petit
Emmanuel Valentin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to AU2003299096A priority Critical patent/AU2003299096A1/en
Publication of WO2004029089A2 publication Critical patent/WO2004029089A2/fr
Publication of WO2004029089A3 publication Critical patent/WO2004029089A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente demande concerne le domaine de la biologie et de la santé. Elle concerne plus particulièrement l'identification et la caractérisation fonctionnelle d'une nouvelle protéine impliquée dans les mécanismes de perméabilité vasculaire, d'adhésion cellulaire et d'angiogénèse, ainsi que l'utilisation de cette protéine comme cible thérapeutique, diagnostique ou de criblage, Elle porte également sur des outils utilisables pour la mise en oeuvre de méthodes thérapeutiques, diagnostiques ou de criblage, comme notamment des sondes, anticorps, vecteurs, cellules recombinantes, etc. L'invention est particulièrement utile pour la préparation de composés pharmaceutiques dans le domaine des cancers, de l'angiogenèse, des maladies inflammatoires ou des altérations tissulaires.
PCT/FR2003/002810 2002-09-25 2003-09-24 Nouvelle cible de l’ angiogenese et utilisations Ceased WO2004029089A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003299096A AU2003299096A1 (en) 2002-09-25 2003-09-24 Novel angiogenesis target and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0211853A FR2844713A1 (fr) 2002-09-25 2002-09-25 Nouvelle cible de l'angiogenese et utilisations
FR02/11853 2002-09-25

Publications (2)

Publication Number Publication Date
WO2004029089A2 WO2004029089A2 (fr) 2004-04-08
WO2004029089A3 true WO2004029089A3 (fr) 2004-06-17

Family

ID=31970980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002810 Ceased WO2004029089A2 (fr) 2002-09-25 2003-09-24 Nouvelle cible de l’ angiogenese et utilisations

Country Status (3)

Country Link
AU (1) AU2003299096A1 (fr)
FR (1) FR2844713A1 (fr)
WO (1) WO2004029089A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001029221A2 (fr) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Nouvelles proteines et polynucleotides codant ces proteines
WO2001090304A2 (fr) * 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002014499A2 (fr) * 2000-08-15 2002-02-21 Immunex Corporation Polypeptides de claudines
WO2002024888A2 (fr) * 2000-09-01 2002-03-28 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
WO2002070539A2 (fr) * 2001-03-05 2002-09-12 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002312241A1 (en) * 2001-06-05 2002-12-16 Exelixis, Inc. B3galts as modifiers of the p53 pathway and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046403A1 (fr) * 1998-03-11 1999-09-16 Exonhit Therapeutics S.A. Criblage differentiel qualitatif
WO2001029221A2 (fr) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Nouvelles proteines et polynucleotides codant ces proteines
WO2001090304A2 (fr) * 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2002014499A2 (fr) * 2000-08-15 2002-02-21 Immunex Corporation Polypeptides de claudines
WO2002024888A2 (fr) * 2000-09-01 2002-03-28 Genentech, Inc. Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
WO2002070539A2 (fr) * 2001-03-05 2002-09-12 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM EMBL; 29 September 2000 (2000-09-29), XP002250864, Database accession no. AK024551 *
DATABASE GSN GENESEQ; 20 January 2003 (2003-01-20), XP002250865, Database accession no. ABZ11501 *
DATABASE GSP [online] GENESEQ; 24 May 2002 (2002-05-24), XP002272083, Database accession no. ABB90003 *
DATABASE GSP GENESEQ; 20 January 2003 (2003-01-20), XP002250866, Database accession no. ABP69284 *

Also Published As

Publication number Publication date
AU2003299096A1 (en) 2004-04-19
AU2003299096A8 (en) 2004-04-19
FR2844713A1 (fr) 2004-03-26
WO2004029089A2 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2005111627A3 (fr) Procedes et produits associes a l'analyse amelioree de glucides
WO2004029093A3 (fr) Anticorps anti-granulocytes chimeres, humains et humainises
WO2005040418A3 (fr) Compositions pour le diagnostic et le traitement de maladies associees a l'expression aberrante des futrins (r-spondins) et/ou wnt
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2004074486A3 (fr) Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
WO2001064877A3 (fr) Gene humain de la schizophrenie
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2003083078A3 (fr) Nouvelle proteine de surface cellulaire avec replis d'hemoglobine, bgs-19
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2002079398A3 (fr) Polypeptides therapeutiques, les acides nucleiques les codant et leurs procedes d'utilisation
WO2009016231A3 (fr) Compositions et procédés permettant de détecter des troubles liés à l'histamine
WO2004029089A3 (fr) Nouvelle cible de l’ angiogenese et utilisations
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2004005487A3 (fr) Polynucleotides codant une nouvelle proteine tubuline tyrosine ligase bgs42 specifique aux testicules
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2007143578A3 (fr) Protéines de perforine-2
WO2004113386A3 (fr) Protéines d'hirudine modifiée et épitopes de lymphocytes t dans l'hirudine
WO2004058986A3 (fr) Acides nucleiques, proteines et anticorps btl-ii
WO2001074851A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2004056991A3 (fr) Nouvelle cible moleculaire de l'angiogenese et utilisations
WO2005003299A3 (fr) Polynucleotides codant de nouvelles proteines de liaison au guanylate (gbp)
WO2002061086A3 (fr) Nouvelle sequence repetee riche en leucine renfermant une proteine exprimee principalement dans l'intestin grele, hlrrsi1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP